Regeneron Pharmaceuticals, Inc. (REGN)
799.45
+5.26
(+0.66%)
USD |
NASDAQ |
Aug 31, 16:00
800.00
+0.55
(+0.07%)
After-Hours: 20:00
Regeneron Pharmaceuticals Cash from Operations (TTM) : 4.681B for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 4.681B |
| March 31, 2026 | 5.013B |
| December 31, 2025 | 4.979B |
| September 30, 2025 | 5.071B |
| June 30, 2025 | 4.744B |
| March 31, 2025 | 3.953B |
| December 31, 2024 | 4.420B |
| September 30, 2024 | 4.247B |
| June 30, 2024 | 4.070B |
| March 31, 2024 | 4.739B |
| December 31, 2023 | 4.594B |
| September 30, 2023 | 5.224B |
| June 30, 2023 | 4.739B |
| March 31, 2023 | 4.281B |
| December 31, 2022 | 5.015B |
| September 30, 2022 | 5.668B |
| June 30, 2022 | 8.452B |
| March 31, 2022 | 8.514B |
| December 31, 2021 | 7.081B |
| September 30, 2021 | 5.940B |
| June 30, 2021 | 2.272B |
| March 31, 2021 | 2.589B |
| December 31, 2020 | 2.618B |
| September 30, 2020 | 2.174B |
| June 30, 2020 | 2.986B |
| Date | Value |
|---|---|
| March 31, 2020 | 2.231B |
| December 31, 2019 | 2.43B |
| September 30, 2019 | 2.371B |
| June 30, 2019 | 2.267B |
| March 31, 2019 | 2.473B |
| December 31, 2018 | 2.195B |
| September 30, 2018 | 2.033B |
| June 30, 2018 | 1.995B |
| March 31, 2018 | 1.570B |
| December 31, 2017 | 1.307B |
| September 30, 2017 | 1.118B |
| June 30, 2017 | 1.354B |
| March 31, 2017 | 1.784B |
| December 31, 2016 | 1.473B |
| September 30, 2016 | 1.377B |
| June 30, 2016 | 1.619B |
| March 31, 2016 | 1.463B |
| December 31, 2015 | 1.331B |
| September 30, 2015 | 1.247B |
| June 30, 2015 | 517.94M |
| March 31, 2015 | 602.13M |
| December 31, 2014 | 743.16M |
| September 30, 2014 | 821.66M |
| June 30, 2014 | 750.55M |
| March 31, 2014 | 550.93M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 885.89M |
| AbbVie, Inc. | 19.51B |
| Gilead Sciences, Inc. | 13.55B |
| Amgen, Inc. | 12.48B |
| Biogen, Inc. | 2.879B |